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Abstract
Background: eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is an
internet based system for patients to self-report symptoms and side effects (adverse events or AE) of cancer
treatments. eRAPID allows AE reporting from home and patient reported data is accessible via Electronic Patient
Records (EPR) for use in routine care. The system can generate alerts to clinical teams for severe AE and provides
patient advice on managing mild AEs. The overall aims of eRAPID are to improve the safe delivery of cancer
treatments, enhance patient care and standardise AE documentation.
Methods: The trial is a prospective randomised two-arm parallel group design study with repeated measures and
mixed methods. Participants (adult patients with breast cancer on neo-adjuvant or adjuvant chemotherapy,
colorectal and gynaecological cancer receiving chemotherapy) are randomised to receive the eRAPID intervention
or usual care over 18 weeks of treatment. Participants in the intervention arm receive training in using the eRAPID
system to provide routine weekly adverse event reports from home. Hospital staff can access eRAPID reports via the
EPR and use the information during consultations or phone calls with patients.
Prior to commencing the full trial an internal pilot phase was conducted (N = 87 participants) to assess recruitment
procedures, consent and attrition rates, the integrity of the intervention information technology and establish
procedures for collecting outcome data. The overall target sample for the trial is N = 504.
The primary outcome of the trial is quality of life (FACT-G) with secondary outcomes including health economics
(costs to patients and the NHS), process of care (e.g. contacts with the hospital, number of admissions, clinic
appointments and changes to treatment/medications) and patient self-efficacy. Outcome data is collected at
baseline, 6, 12, 18 weeks and 12 months. The intervention is also being evaluated via end of study interviews with
patient participants and clinical staff.
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Discussion: The pilot phase was completed in February 2016 and recruitment and attrition rates met criteria for
continuing to the full trial. Recruitment recommenced in May 2016 and is planned to continue until December
2017. Overall findings will determine the value of the eRAPID intervention for supporting the care of patients
receiving systemic cancer treatment.
Trial registration: Current Controlled Trials ISRCTN88520246. Registered 11 September 2014.
Keywords: Cancer, Adverse events, Patient reported outcome measures (PROMs), Patient reported outcomes (PROs),
Electronic patient records, Electronic health records, Internet, Intervention, Self-management, Chemotherapy
Background
Systemic drug treatments for cancer (chemotherapy,
hormonotherapy, biological therapy, targeted agents)
are associated with significant adverse events (AEs). An
AE is an untoward symptom or disease associated with
(but not necessarily causally related to) a medical treat-
ment or intervention AEs may lead to changes in drug
dosage, cessation of treatment and can significantly
compromise patients’ quality of life. Severe AEs can es-
calate to hospitalisation for potentially life-threatening
toxicities: 18% of cancer patients present to emergency
services within 14 days of a scheduled hospital visit for
symptom management (infection, fever, nausea/vomit-
ing, pain, breathlessness) [1–4]. Patients with breast,
gastrointestinal, colorectal cancers and those with
metastatic disease are amongst those most likely to
have emergency admissions [4, 5].
Many patients however, delay seeking care especially
out of hours [3, 5]. This concurs with the findings of a
UK enquiry into patient outcome and death (National
Confidential Enquiry into Patient Outcome and Death,
NCEPOD) which found that of patients dying within
30 days of systemic cancer therapy, 17% delayed seeking
advice for over 24 h [6]. AEs are documented consist-
ently by physicians in clinical trials however in routine
care recording of AEs by clinicians and reporting by
patients is variable and often omitted [6]. It has been
recognised for some time that a structured AEs report-
ing system would be useful to facilitate correct docu-
mentation and grading of AE severity to support tailored
management. Consequently, the National Cancer Insti-
tute (NCI) in the US have developed the Common
Terminology Criteria for Adverse Events (CTCAE v 4.0)
[7] as a reporting and severity grading system for cancer
clinical trials. These have recently been adapted for pa-
tients to self-report (NCI-PRO CTCAE) [8] and these
items have concordance with nurse evaluated AE [9] and
similar items created for self-report correlate with quality
of life measures [10]. The need for routine monitoring of
cancer treatment AE is at odds with a health care system
relying increasingly on patient self-management and home
based care. In order to bridge the gap in service provision
to detect, identify and manage AE in cancer patients the
Electronic patient self-Reporting of Adverse-events:
Patient Information and aDvice (eRAPID): system was
developed [11].
Patient reported outcome measures (PROMs)
PROMs have been used in clinical practice to support
care of individual patients, recent reviews suggest they
improve symptom/function monitoring, physician pa-
tient communication and decision making [12–17], can
save time during clinic visits and improve the accuracy
of symptom reporting [18]. In the UK the 2008 Darzi re-
port [19] recommended that collection of PROMs data
should be an essential component of health care evalu-
ation [19] and the Department of Health (DOH) subse-
quently produced guidelines to aid their implementation
[20]. Following this, use of PROMs in the health service
is most advanced in England (particularly for perform-
ance comparisons) [21]. Two recently published reports
by the Independent Cancer Taskforce and NHS England
have continued to highlight the need to put PROMs at
the centre of strategies to improve patient centred can-
cer care and quality of life [22, 23].
Electronic and mobile reporting technology
Electronic reporting of patient reported outcome mea-
sures (PROMs) has proven extremely acceptable to pa-
tients in the clinic setting [24–26]. Examples of successful
implementation of electronic symptom reporting in oncol-
ogy clinical practice include PatientViewpoint [27], the
symptom tracking and reporting system (STAR) system
for patients to report chemotherapy AE [28] and the Tell
Us™ [29] system for advanced cancer patients in hospices
undergoing palliative care (all in the U.S.). In Austria the
Computer-based Health Evaluation System (CHES) soft-
ware [30] has been developed and an interactive online
system (ISAAC) is in use in Canada [31]. In the UK the
ASyMS mobile phone system is currently being evaluated
[32]. Electronic patient reported outcome systems have
proven very acceptable even for patients coping with
extreme symptom burden and reduced quality of life; in-
deed a mean monthly PROM completion rate of 83% at
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34 weeks has been achieved with patients receiving cancer
treatment [33].
eRAPID development work
The eRAPID research programme was designed to de-
velop and evaluate an online system to support the col-
lection and clinical integration of patients’ symptom/AE
reports during cancer treatment. It utilises a web-based
questionnaire builder system called QTool. QTool Ver-
sion 1 was originally used in a large prospective study of
cancer survivors, recruiting 636 patients in 12 months,
81% of whom completed web-based questionnaires at
baseline [34] (www.epocs.leeds.ac.uk), confirming the
feasibility of web-based patient-reporting and QTool
acceptability. Between 2010 and 2013 the eRAPID
developmental work was conducted (funded by an
National Institute of Health Research grant: Programme
Development Grant scheme RP-DG-1209-10,031), which
focused on:
1) Developing the electronic platform to allow QTool
data to be securely linked to the electronic patient
records used by Leeds Teaching Hospitals (see Fig. 1).
2) Selection, adaption and evaluation of items for
patients to report symptoms and AE resulting in the
development of patient-reported AE (PRAE) items
based on CTCAE grades [35]. The initial item pool
includes most common AEs namely nausea, vomiting,
diarrhoea, mucositis, fatigue, insomnia, palmar-plantar
erythema, pain, peripheral neuropathy, appetite loss,
constipation, rash, bleeding, anaemia, febrile
neutropenia and stoma problems.
3) Collating patient information and advice on AE
management. We reviewed and compiled the
extensive literature available providing patient advice
on the management of common symptoms and side
effects during systemic cancer treatment. The
information is available on the password protected
eRAPID patient website. The eRAPID QTool
symptom report provides patients with immediate
brief graded advice dependent on severity of AE
reported (including a recommendation to contact the
hospital when severe symptoms are detected) and
links users out to the eRAPID website for more
detailed information. The website has been extensively
reviewed by both patients and oncology staff.
4) Mapping patient care pathways. With support from
staff responsible for monitoring chemotherapy
patients at St James’ Institute of Oncology, Leeds the
current care pathways for patients receiving
systemic treatment were mapped to establish where
eRAPID can best fit. This work was conducted via:
Fig. 1 eRAPID system overview
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staff interviews, a local audit of care pathways/acute
triage processes, mapping the existing
chemotherapy pathways for the detection and
management of AE and an assessment of patient
experience of acute admissions and prospective
patient interviews and diaries during chemotherapy
to record AEs and costs to patents and services.
The latter aimed to develop a questionnaire for
health economic analysis [5].
This developmental work led to the:
 Successful mapping of current systemic treatment
pathway, establishing where eRAPID is best placed
 Identification of staff requiring training to deliver
eRAPID
 Adaptation of a health economic questionnaire for
cancer patients receiving treatment
The eRAPID intervention
An overview of the eRAPID intervention is described in
Figs. 1, 2a and b. Figure 1 represents the technical com-
ponents and their integration to support reporting of
AEs immediately available in the EPR. The architecture
protects patient confidentiality providing security whilst
allowing immediate linkage to individual patient records
to support care.
The intervention consists of the following components:
 Patients can log in to QTool (using a unique
username and password) to access the eRAPID
symptom questionnaire anywhere with internet
access (including home or hospital).
 For mild/moderate problems information about
self-managing these issues are provided via brief
instructions in QTool along with hyperlinks to
more detailed advice on the eRAPID patient
website (Fig. 2a).
 Where severe symptoms are reported patients are
advised to contact the hospital.
 The patient reported data is immediately available
for staff to view in the individuals’ electronic patient
records in Leeds Teaching Hospitals NHS Trust
(Patient Pathway Manager, PPM). See Fig. 2b.
 Alerts for severe symptom reports are sent directly
to staff via email. Clinicians can then log into PPM
and view the patients’ symptom reports and take
appropriate action where needed.
Prior to the start of the current trial the eRAPID system
underwent usability testing with N = 14 breast cancer pa-
tients receiving adjuvant or neo-adjuvant chemotherapy
and relevant staff.
Hypotheses
We hypothesise the eRAPID intervention has the poten-
tial to bring benefit to patients, staff and the NHS in the
following ways:
 Benefits for patients
○ Earlier symptom detection and improved self-
management, timely admissions
○ Improved supportive medication use
○ Appropriate hospital, GP, community contacts
○ Better outcomes (improved symptom control,
functioning and quality of life)
 Benefits for staff
○ Reduce the number of hospital, GP, community
contacts
○ Save time spent on enquiring and recording AEs
○ Focus attention during clinical contacts on most
important or severe AEs
○ Support decision making in routine care
 Benefits to the NHS
○ eRAPID provides a cost-effective approach to
support patient self-management and reduce
hospital and GP contacts
Study design
This study is a single centre 1:1 allocation prospective
randomised two-arm parallel group trial design with re-
peated measures and mixed methods.
Patient sample
The study sample includes patients with gynaecological
or colorectal cancer requiring chemotherapy, or breast
cancer undertaking either neo-adjuvant or adjuvant
following systemic treatment pathways at St. James’s
Institute of Oncology, Leeds, UK.
Methods
Participants are randomised to either the intervention arm
(eRAPID plus usual care) or the control arm (usual care).
See Fig. 3 for the trial flow diagram. Participants are on
the study for an 18 week period from the start of chemo-
therapy. A subset of participants (where feasible within the
funding timeframe) will also be assessed at a 12 month
time point to examine any potential longer term impact of
the intervention on quality of life and clinical processes.
Usual care
Includes an initial consultation with an oncologist to de-
cide whether to commence systemic treatment. Patients
are provided with verbal and written information on
treatment benefits and expected AEs, and are given in-
structions on how to contact the hospital. They have a
nurse assessment before starting their treatment. During
treatment patients are routinely assessed in clinics for
Absolom et al. BMC Cancer  (2017) 17:318 Page 4 of 16
AE and to prescribe their next cycle of treatment by an
oncologist, Clinical Nurse Specialist (CNS) or staff grade
doctor. Depending on AE experienced by the patient,
treatment doses can be reduced, and/or supportive med-
ications changed (e.g. anti-sickness drugs, anti-diarrhoea
drugs). When at home if patient has a serious AE they
are asked to contact the hospital and the nurse dealing
with the patient phone call uses an Acute Triage Form
to record reasons for the call, document the AE and
gives advice.
eRAPID intervention
In addition to usual care, participants randomised to the
eRAPID intervention arm will receive training on using
the system and will be asked to complete the eRAPID
symptom report routinely from home at least weekly and
a
b
Fig. 2 a Screenshots of eRAPID intervention (Patient login and symptom reports). b Screenshots of eRAPID intervention- Clinician view of
symptom reports in electronic patient record (EPR)
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when they experience symptoms over 18 weeks during
treatment. Clinicians are given access to patients’ self-
reported AEs via the electronic patient record system
(PPM) and asked to utilise the information when seeing
patients in clinic or providing telephone advice.
Aims and study objectives
To evaluate the potential benefits of eRAPID for patients
and staff, the intervention and usual care arm will be
compared on the following areas through the collection
of appropriate clinical information, patient reported out-
comes and interview data:
1. Assessment of hypothesised benefits to patients with
mild or moderate AE:
a) Number of hospital, GP and community contacts
during the study
b) Improved patient reported outcomes
c) Improved symptom detection and supportive
medication use
2. Assessment of hypothesised benefits to patients with
severe AE:
a) Improved detection and treatment of AEs and
admissions (e.g. number of clinician alerts generated
from eRAPID, number of admissions and hospital
contacts)
b) Levels of morbidity (percentage of planned
chemotherapy received, changes to treatment plans
(dose reductions, dose delays/interruptions)).
3. Assessment of hypothesised benefits to clinicians:
Staff will be interviewed about their views of the
value of eRAPID in saving time currently spent
enquiring and recording patients’ AE and supporting
treatment decision-making. In addition oncologists
will complete a feedback form at routine review
appointments after seeing eRAPID intervention par-
ticipants to assess how/if patient reports are used.
4. Monitor patient safety, assessed by monitoring acute
admissions, cumulative deaths and cause of death.
The FACT-G Physical Wellbeing Score [36] (measured
at 18 weeks) is the primary outcome. The main second-
ary outcome is cost effectiveness assessed via use of
health care services (including hospital admissions,
telephone contacts and consultations, medication and
personal expenses). In addition participant records will
Fig. 3 Trial flow diagram
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be linked to costs held within the local pilot database of
the National Patient-Level Information and Costing
System (PLICS) scheme. This provides a cost for hospital
based accident and emergency department visits, out-
patient attendances and inpatient stays.
Ethical approval
The study was approved by the National Research Ethics
Service (now part of the Health Research Authority)
Yorkshire & The Humber Leeds East Committee in
September 2014 (Reference 14/YH/1066). Local approvals
from the Leeds Teaching Hospitals NHS Trust Research
and Innovation Department were also obtained.
The RCT has two phases
I. An internal pilot phase to assess the feasibility and
acceptability of the intervention and allow for minor
modifications before further large scale recruitment
was conducted. If no meaningful changes are made
to the intervention the study would progress to the
main trial and patients recruited during the pilot
phase will be included in the analysis.
II. The full trial phase will continue to recruit the
target sample (at most N = 504 participants, see
sample size calculation below) using the best
recruitment and retention methods established in
the internal pilot.
Internal pilot phase
Prior to starting the full trial an internal pilot phase was
conducted with the aim of assessing recruitment and at-
trition rates, refining the intervention, testing the integ-
rity of information technology (IT) systems and to
establish procedures and methods for collecting out-
come measure data. We aimed to achieve (i) recruitment
levels of >10 patients per month), (ii) 60% to consent to
randomisation, and (iii) <30% attrition.
The pilot sample size was set at 30 participants per-
arm [37] allowing for 30% overall attrition, the overall
target was a minimum of 42 patients per-arm (N = 84).
Recruitment took place between January–September
2015.134 patients were approached, 87 consented, 22 de-
clined and 25 were excluded after further screening (no
Internet access or not continuing on to chemotherapy).
The consent rate when including those patients excluded
post-screening was 65% (87 consented/134 approached).
However the “true” consent rate excluding the 25
patients was 80% (134 approached - 25 ineligible). Forty-
four participants were allocated to the Intervention arm
and 43 to Usual Care. Only 13 participants (15%) with-
drew. No significant problems with the IT systems
underpinning the eRAPID online intervention were en-
countered and the research team was able to develop
robust methods of gathering information on clinical
process data (e.g. hospital contacts, changes to treat-
ment). Based on participant feedback some refinements
were made to patient “use of resources forms” to aid
comprehension of questions and ease of completion.
The overall recruitment and attrition targets were met
and the Trial Steering Committee (TSC) recommended
progression to the main trial. The study procedures
described below reflect the protocol for the main trial
approved by Yorkshire & The Humber Leeds East
Research Ethics Committee in December 2016, protocol
version number 1.5.
Patient eligibility
Inclusion criteria
 Adult patients (aged 18 years or over) attending St
James’ Institute of Oncology, Leeds with breast
cancer undertaking either neo-adjuvant or adjuvant
systemic treatment pathways, gynaecological or
colorectal cancer requiring chemotherapy
 Prescribed at least 3 months of planned
chemotherapy cycles at the time of study consent
 Able and willing to give informed consent
 Able to read and understand English
 Access to the internet at home
Exclusion criteria
Patients are excluded from participation if they are:
 Taking part in other clinical trials involving the
completion of extensive patient reported outcome or
quality of life measures or have previously
participated in an eRAPID trial
 Exhibiting overt psychopathology/cognitive
dysfunction
Recruitment processes
Identification of eligible patients
Patients are recruited from outpatient clinics and day
case wards at St James’ Institute of Oncology clinics.
Eligible patients are identified by screening of the
clinic, in-patient or day-case lists by the most appropri-
ate clinical staff. Prior to study commencement, consul-
tants responsible for the care of patients within each
eligible tumour group are contacted via email and sent
an introduction to the study and permission is requested
for the research team to approach their patients.
Approaching patients
An appropriate member of the clinical team seeks per-
mission from eligible patients for the researcher to speak
to them about the study. After introduction from clinical
staff, eligible patients are approached by a member of
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the research team who explain the study and provide the
information sheet. Patients are given as much time as
they need to read the information and ask questions and
should they wish to participate they are consented at the
visit. Where patients prefer more time to consider
participation, they can take the information home and
discuss the study again with the researcher at their next
visit.
When patients are happy to participate they are asked
to provide written informed consent. The participant is
then randomised to either the intervention or control
arm. Participants who are randomised to the interven-
tion arm receive training in using the eRAPID system.
Randomisation
After trial eligibility has been confirmed and consent
given, randomisation is performed via the University of
Leeds Clinical Trials Research Unit (CTRU) telephone
system. Participants are randomised with 1:1 allocation
to intervention and control groups. Patients are stratified
by cancer site (breast, gynaecological or colorectal), gen-
der and previous chemotherapy (gynaecological cancer
patients only) in variable random permuted blocks of 4,
6 or 8, see Fig. 4.
eRAPID intervention: Participant and staff training
Participant training
Researchers provide a short demonstration on how to
use the eRAPID system and provide patients with a
unique user name and password to access the system,
on an eRAPID ‘postcard’. Participants are given a user
manual to take home providing a step-by-step guide on
how to log in and use the eRAPID system. Participants
are asked to complete the remote eRAPID Adverse
Events (AEs) questionnaire weekly (from home or during
clinic visits) and at any time when they experience any
side-effects/symptoms during the duration of their treat-
ment. The questionnaire consists of 12–15 items de-
pending on the disease group assessing the severity of
common symptoms such as: nausea, vomiting, pain,
fatigue, diarrhoea, constipation, sore mouth/tongue,
temperature, chills, performance status, fatigue, sleep,
and appetite. Participants can also provide details about
additional problems at the end of the standard ques-
tions. A weekly text message or email reminder are sent
to the participants as a prompt to complete the eRAPID
AE questionnaire.
Staff training
Prior to study commencement the appropriate staff re-
ceived training on eRAPID. The aims of training are to
support staff in understanding:
1. How patients use and interact with eRAPID and the
content of self-reported AE questionnaire/website
2. Accessing patients’ eRAPID self-report data in the
electronic patient records
3. Interpreting patient self-reported AE scores and
methods of incorporating the data into clinical
encounters with patients. Including information on
how the symptom scores relate to mild, moderate
and severe problems and how the cut-offs or alerts
for severe symptoms have been developed
During one-to-one/small group interactive sessions
eRAPID is demonstrated by the research team, giving
staff an opportunity to see the patient interface. Staff are
shown the practicalities of locating the data within the
electronic patient records. Manuals are provided outlin-
ing the key steps in all the processes covered in the
session. Training highlights that the self-report informa-
tion should be seen as a supplementary resource for staff
to use in conjunction with routine practices for clinical
decisions.
Outcome measures
The following measures and data are being collected to
enable comparison between the usual care and eRAPID
intervention arms. An overview of the outcome data and
time points are outlined in Tables 1 and 2.
Fig. 4 Stratification factors used in randomising patients in the eRAPID RCT
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Table 1 eRAPID RCT in systemic cancer treatment: Participant completed primary and secondary outcomes measures
Questionnaire title and brief description Item information/response format
and scoring
Example questions Time points
Primary outcome- Quality of Life
Quality of life: FACT-G [36]
27 item cancer specific QOL measure four
subscales covering physical, social or family,
emotional and functional wellbeing
5 point scale (0 not at all – 4 very much) • I have nausea Baseline, 6, 12, 18
weeks and 12
months• I am forced to spend time in spend
Higher subscale and total scores indicate
better QOL (score range 0–108).
• I get support from my friends
• I worry that my condition will get worse
• I have accepted my illness
Secondary outcomes- health economic/clinical process data
EQ-5D-5 L [38]
6 item descriptive health profile (measuring
mobility, self-care, usual activities, pain,
anxiety/depression) and a single index value
for health status that can be used as part
of a health-economic evaluation.
5 items measured on 5 point scale and
single global health item rated from 0
(worst health) to 100 (best health)
Self-care Baseline, 6, 12, 18
weeks and 12
months• I have no problems washing of
dressing myself
• I have slight problems washing
or dressing myself
• I have moderate problems
washing or dressing myself
• I have severe problems washing
or dressing myself
• I am unable to wash or dress
myself
Use of Resources
Assessment of financial impact of cancer
treatment covering:
Varied tick boxes and free text options. • Please complete the boxes below
to tell is about any non-hospital
health care contacts you have had
in the last 6 weeks
6, 12, 18 weeks
and 12 months
- Employment status
- Contacts with community health care
services (GP, district nurses etc)
- Medications costs • Please tell us about any medications
you have been prescribed in the last
6 weeks and who prescribed it- Cancer related travel costs
- Cancer related food/drink costs
- Additional expenses • Please tell us about any additional travel
costs related to your cancer or cancer
treatment you have incurred in the
last 6 weeks
EORTC-QLQ C30 [39]
30-item questionnaire with five functional
scales (physical, emotional, cognitive, social,
role), three symptom scales (fatigue, pain,
nausea/vomiting), a global health related
quality of life scale, and six single items
(anorexia, insomnia, dyspnoea, diarrhoea,
constipation, financial difficulties)
Questions are rated on a 4 or 7 point
response scales.
• Do you have any trouble taking a long
walk
Baseline, 6, 12, 18
weeks and 12
months
• During the past week…The scales and single-item responses are
recalculated into a score from 0 to 100.
- Have you lacked appetite?
• A high functional scale score represents a
high level of functioning
- Were you tired?
- Did you feel depressed?
• A high score for the global health
status/QOL represents a high QOL
• A high score for a symptom scale/item
represents a high/worse level of
symptomatology
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Table 1 eRAPID RCT in systemic cancer treatment: Participant completed primary and secondary outcomes measures (Continued)
Secondary outcomes- Self-efficacy
Self-Efficacy for Managing Chronic Disease [34]
6-Item scale covering several domains common
across chronic diseases (symptom control, role
function, emotional functioning and
communicating with physicians)
Items rated from 1- (not at all confident)
to 10 (totally confident)
• How confident are you that you can
keep physical discomfort or pain of your
disease from interfering with the things
you want to do?
Baseline and
18 weeks
The score for the scale is calculated from
the mean of the six items.
• How confident are you that you can do
things other than just taking medication
to reduce how much you illness affects
your everyday life?
Cancer Behaviour Inventory-Brief (CBI-B) [40]
A measure of self-efficacy for coping with
cancer. 14 items (adapted from full 33
item measure)
Items are rated on a 9-point scale ranging
from 1 (“not all confident”) to 9 (“totally
confident”)
Please read each numbered item. Then
rate that item on how confident you are
that you can accomplish that behaviour.
Baseline and
18 weeks
- Maintaining independence
- Expressing feelings about cancer
A total score is calculated as the sum
of all 12 items.
- Asking physicians’ questions
- Coping with physical changes
Patient Activation Measure (PAM) [41]
13-item scale for measuring the level of patient
engagement in their healthcare (knowledge,
skill and confidence for self-management)
Statements rated on 4 point scale from
disagree strongly to agree strongly and
additional N/A option.
• When all is said and done I am the
person who is responsible for taking
care of my health
Baseline, 18 weeks
and 12 months
• I am confident I follow through on
medical treatments I may need to
do at home
Responses are combined to provide a
single score of between 0 and 100 with
higher scores representing higher levels
of patient activation.
• I know what treatments are available
for my health problems.
Scores can be classified into one of four
groups, known as ‘levels of activation’.
Secondary outcomes- eRAPID/IT system performance
System Usability Scale (SUS) [42]
10 item instrument to assess views of
usability of an IT systems.
Each statement rated from 1 strongly
disagree to 5 strongly agree.
• I think that I would like to use this
system frequently
18 weeks
• I thought there was too much
inconsistency in this system
Responses are calculated into a total score
ranging from 0 to 100 with higher scores
representing better system usability.
• I felt very confident using the system
eRAPID end of study questionnaire
15 statements/free text boxes to assess
participant views of using eRAPID and
suggestions for improvements
Statements rated on 3–5 response option
scales (e.g. very easy-very difficult) and free
text boxes for comments.
• How easy or difficult was it to learn how
to use the eRAPID system?
18 weeks
• How did you feel about the amount of
time it took to complete the symptom
questions?
• To what extent do you feel that the
symptom questionnaire was useful for
the doctors and nurses you saw during
your treatment?
• Have you got any suggestions about how
the eRAPID system could be improved?
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Patient outcome measures
Functional assessment in cancer therapy scale-General
(FACT-G) [36]
The FACT-G is a cancer specific measure widely used in
clinical trials. It has four subscales: physical wellbeing,
social or family wellbeing, emotional wellbeing, and
functional wellbeing. Question responses range from 0
to 4. Higher scores on the questionnaire indicate better
quality of life.
Eq-5D-5 L [38]
The EQ-5D is a standardised instrument for use as a
measure of health outcome developed by the EuroQol
Group. The instrument assesses five dimensions: mobility;
self-care; usual activities; pain/discomfort and anxiety/de-
pression. Each dimension has five response levels (ranging
from no problems to extreme problems). The instrument
also includes a scale to rate health from 0 (worst health
you can imagine) to 100 (best health you can imagine).
Use of resources
Resource use is assessed using patient forms (detailing
non-hospital contacts e.g. appointments with GPs/com-
munity services, counsellors, local support services), as
well as medication use and costs incurred as a conse-
quence of cancer diagnosis/treatment. This form is
based on those developed by Hulme for a recently com-
pleted trial assessing treatment for chemotherapy-related
nausea/vomiting (https://njl-admin.nihr.ac.uk/docu-
ment/download/2002381).
EORTC-QLQ-C30 [39]
The EORTC QLQ-C30 is a 30-item questionnaire
consisting of five functional scales (physical, emotional,
cognitive, social, role), three symptom scales (fatigue,
Table 2 eRAPID RCT in systemic cancer treatment: Researcher collected data for secondary outcomes
Data Description of data Time point for collection
Treatment and clinical
information
• Cancer diagnosis, stage and grade Initial baseline assessment and reviewed for
changes at 18 weeks
• Age, date of birth
• Baseline data on planned chemotherapy
• Changes to treatment delivery and reason
• Comorbidities
Clinical process- Hospital
contacts
• Contacts with the hospital e.g. (unplanned) telephone,
appointments, consultations
• Data extracted from medical notes for 18
of study
• Emergency admissions, acute ward stays and reasons
for contacts.
• 3 month prior to 12 month follow-up
assessment
Clinical process- Information from
general practice
• GP recorded problems/concurrent illnesses • Data extracted from medical notes for
18 week study period
• Prescribed medications and reasons for prescription
(where available) • 3 month period prior to 12 month follow-up
assessment for subset of participants
IT/System functioning • Researcher maintained log of IT issues (e.g. server downtime,
contacts with study participants reporting IT problems or
issues logging into eRAPID) and how these were resolved
Throughout trial
Treatment and clinical
information
• Cancer diagnosis, stage and grade Initial baseline assessment and reviewed
for changes at 18 weeks
• Age, date of birth
• Baseline data on planned chemotherapy
• Changes to treatment delivery and reason
• Comorbidities
Clinical process- Hospital
contacts
• Contacts with the hospital e.g. (unplanned) telephone,
appointments, consultations
• Data extracted from medical notes for 18
of study
• Emergency admissions, acute ward stays and reasons
for contacts.
• 3 month prior to 12 month follow-up assessment
Clinical process- Information from
general practice
• GP recorded problems/concurrent illnesses • Data extracted from medical notes for 18 week
study period
• Prescribed medications and reasons for prescription
(where available) • 3 month period prior to 12 month follow-up
assessment for subset of participants
IT/System functioning • Researcher maintained log of IT issues (e.g. server downtime,
contacts with study participants reporting IT problems or issues
logging into eRAPID) and how these were resolved
Throughout trial
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pain, nausea/vomiting), a global health related quality of
life scale, and six single items (anorexia, insomnia,
dyspnoea, diarrhoea, constipation, financial difficulties).
Questions are rated on a 4 or 7 point response scale and
overall scale scores are calculated from 0 to 100 with
higher scores indicating better quality of life or function-
ing. Symptoms scales are scored so that higher scores
indicate worse symptoms experience.
Self-efficacy and patient activation
Self-Efficacy for Managing Chronic Disease 6-Item Scale [34]
This 6-item scale covers several domains that are com-
mon across many chronic diseases such as symptom
control, role function, emotional functioning and com-
municating with physicians.
The Cancer Behaviour Inventory- Brief (CBI-B) [40]
A self-efficacy measure specifically designed for assessing
coping with cancer. Devised from the full 33 item meas-
ure, this brief version has 14 items covering: maintaining
activity and independence, seeking and understanding
medical information, stress management, coping with
treatment related side effects and accepting cancer/main-
taining a positive attitude.
The Patient Activation Measure (PAM) [41]
The PAM is a tool for measuring the level of patient
engagement in their healthcare. It was designed to assess
an individual’s knowledge, skill and confidence for self-
management. The PAM 13-item scale explores beliefs,
knowledge and confidence for engaging in health behav-
iours. Each item is rated on a four point scale from
strongly disagree to strongly agree and an overall score
from 0 to 100 can be calculated. These scores can be
subdivided to categorise people into one of four activa-
tion categories ranging from 1- Low activation to 4-
High activation.
Socio-demographic and clinical process data
Participants complete a baseline questionnaire on socio-
demographics and current computer usage. Clinical
baseline data are obtained from participants’ medical
notes and include diagnosis, co-morbidities and planned
treatment (Table 2).
To determine any association between the eRAPID
intervention and improved detection and management
of AEs, data is collected from hospital triage forms,
medical records, hospital databases to record:
 Number of scheduled and unscheduled hospital
contacts (admissions, clinic visits, phone calls
with staff )
 Changes to supportive medications and
chemotherapy dose changes
 Contacts with GP and community services
 Number of clinician alerts generated from eRAPID
severe symptom reports and actions taken by staff
eRAPID system performance
Throughout the study the eRAPID IT system is moni-
tored for unscheduled server down time (leading to the
unavailability of the QTool questionnaire website, eRA-
PID website and patient symptom data in PPM). A log
of phone calls/feedback from study participants regard-
ing issues/problems surrounding the use of the eRAPID
questionnaire or website will be maintained.
eRAPID intervention participants are asked to complete
the System Usability Scale [42] (SUS). This 10 item instru-
ment assesses subjective views of usability of different
systems including hardware, software, mobile devices,
websites and applications. The 10 items cover the ease of
using the system, its complexity and user confidence. Each
item is rated from 1 to 5 and a composite score of overall
usability can be calculated ranging from 0 to 100 (higher
scores reflect better usability). Intervention participants
are also asked to complete a short end of study question-
naire about their experiences with the eRAPID interven-
tion which includes free text boxes for comments and
feedback.
Participant interviews
Between 5 and 10 participants per disease group and
study arm will be interviewed at the end of the full trial.
Participants will be asked about their treatment experi-
ence, how they managed and monitored their symptoms
and perceptions of reporting and discussing their symp-
toms with hospital staff. Intervention arm participants
will be asked to describe their thoughts on using the
eRAPID system.
Staff feedback- interviews and questionnaires
At routine chemotherapy review appointments involving
eRAPID intervention patients, staff will be asked to
provide:
 Clinician reports of use of eRAPID patient data
during consultations
 At 6 weeks routine clinic visits clinicians are asked
to complete CTCAE scoring form matching those
AE completed by patients on the eRAPID
questionnaire
At the end of the study 5 health professionals from
each disease group will be interviewed to determine
their views of eRAPID, the perceived value and use of
the patient data in clinical practice (e.g. improving the
detection, documentation and management of AE,
supporting treatment decision-making in routine care).
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Perceptions of staff training needs and recommendations
for improving the system will also be explored.
Sample size calculations
The sample size for the full trial is based on the primary
patient outcome of better symptom control measured at
18 weeks by the FACT-G. A sample of 176 patients per
arm is necessary to detect a 2-point change in the
FACT-G Physical Wellbeing score with 80% power and
5% significance, where the population standard deviation
is 6.7. This change corresponds to a medium Cohen’s
effect size (0.3) [43].
Allowing for 30% attrition, a minimum of 252 patients
per arm (504 total) is required. With potentially >500
eligible patients treated in the cancer centre annually,
we expect to recruit 20 patients per month over approxi-
mately 24–30 months, allowing for 70% internet access
and 70% consent rate.
Analysis populations
All analyses and data summaries will be conducted on the
intention-to-treat (ITT) population which is defined as all
participants registered regardless of non-compliance with
the protocol or withdrawal from the study.
Statistical analysis
Baseline characteristics
Data from the baseline socio-demographic, computer
usage and clinical data questionnaires will be tabu-
lated using frequencies and summary statistics for
each treatment group and overall for both the pilot
phase and full trial.
Primary outcome
The FACT-G Physical Well-being score will be sum-
marised overall and by treatment arm. Changes in score
over time and differences between treatment arms will
be explored using a multilevel repeated measures model.
The model for each post-randomisation point will be
adjusted for baseline score and stratification factors. If
there are missing items, subscale scores will be prorated
as per the FACT-G scoring manual.
Secondary outcomes
Clinical process measures
The number of calls made to the hospital will be
summarised overall and by treatment arm. Differences
between the two treatment groups will be compared
using either Poisson regression or negative binomial re-
gression; the most appropriate model will be chosen
after performing post-estimation tests. Models will be
adjusted for the stratification factors.
The numbers of weekly/additional AE reports and
severe AE alerts generated will be summarised for
participants randomised to the eRAPID intervention.
The number of telephone calls to hospital staff, acute
admissions, contacts with GP and/or community ser-
vices and number of deaths will be summarised overall
and by treatment arm. Any differences between treat-
ment arms will be explored using the most appropriate
regression model (either Poisson or negative binomial,
to be decided using post-estimation tests) adjusted for
stratification factors.
Patient outcome measures (other than primary)
Changes in scores over time and differences between
treatment arms will be explored using a multilevel re-
peated measures model adjusted for baseline scores and
stratification factors. As the sample size was not pow-
ered to detect changes in these outcome measures,
statistical significance will be assessed at the 1% level.
Health-economic data
An embedded health-economic study will allow within
trial incremental cost-effectiveness analysis (18 weeks)
taking the perspective of the service provider including
the costs of NHS and Personal Social Services. The ana-
lysis will compare usual care with the eRAPID-supported
pathway. A secondary analysis will take a societal perspec-
tive. Analyses will use quality-adjusted-life-years (QALYs)
outcome-measures. Estimation of QALYs requires the
production of utility-weights for each health-state ob-
served in the trial population. We will use the EQ-5D-5 L
for this purpose [3, 44] collected at baseline, 6, 12 &
18 weeks. We will also use EORTC QLQ-C30 to derive
utilities (EORTC QLQ-U10) to calculate QALYs in the
same way. This will limit the need to interpolate quality of
life between observation points [45]. NHS resource-use
associated with each treatment modality will be collected
using the process-of-care measures to contribute to a
health-economics analysis of additional health financial
costs related to treatment and the study. Use of outpatient
and community-based health and social care (including,
for example, home help or residential care) will be col-
lected from the patient at baseline, 6, 12, and 18 weeks
with the Use of Resources questionnaire developed in the
Programme Development Grant and tested in the pilot
study. Unit financial costs for health services resources
will be obtained from national source: the Personal Social
Services Research Unit, the British National Formulary
and NHS reference cost database [46–48]. Given the dur-
ation of the trial discounting is not required.
Secondary analysis will include costs to participants
(travel expenses, over the counter medicines) and prod-
uctivity losses.
In addition to the analyses at 18 weeks we will under-
take an exploratory cost effectiveness analysis (including
a planned a–priori sub-group cost-effectiveness analysis
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at 12 months using a sub-sample of participants for
whom we have collected resource use, EQ-5D-5 L and
EORTC QLQ-C30 data).
For each analysis we will undertake probabilistic sensi-
tivity analysis using bootstrapping. The results will be
presented as the Expected Incremental Cost Effective-
ness Ratio, scatter plot on the cost-effectiveness plane
and a Cost Effectiveness Acceptability Curve. We will
calculate the expected net-benefit assuming lambda has
a value of £20,000 [49].
Qualitative data
Interviews will be recorded and transcribed. Data will be
managed by NVivo software and analysed using the-
matic analysis [37, 50]. Two researchers will independ-
ently look for the emerging themes and code them.
Then they will meet, compare the codes/themes and
resolve any potential conflicts by consensus.
Discussion
This paper describes the protocol for the eRAPID RCT
in systemic cancer treatment. eRAPID is a unique web
based intervention designed to improve the systematic
reporting of AE during cancer treatment and improve
patient care and experiences. A number of web based
PROMs systems have been developed. Since the current
trial began Basch and colleagues in the U.S. have pub-
lished findings from an RCT using the STAR (Symptom
Tracking and Reporting) web interface during chemo-
therapy indicating a positive impact on patients’ quality
of life, treatment delivery, number of emergency room
attendances and 1 year survival [44]. We believe eRAPID
is the first of its kind to allow remote monitoring of
symptoms and side effects where patient reported data is
accessible alongside standard clinical information in
electronic patient records as well as providing patients
with immediate symptom management advice. We hy-
pothesise that these features along with alerts for severe
symptoms will lead to improved clinical outcomes for
participants allocated to the eRAPID intervention and
will benefit health care services.
This study can be considered a complex interven-
tion due to the number of active components in-
volved. These include the new technology for patients
completing symptom self-reports from home, auto-
matic advice on managing mild symptoms and when
to contact the hospital for severe problems, the avail-
ability of this patient data for staff to use in clinical
practice, alert generation for severe problems and
maintaining staff training and engagement. Conse-
quently eRAPID’s success relies on the investment of
both staff and patient groups in the intervention and
the robustness of the IT supporting the system.
Although the eRAPID website and the online
symptom reporting questionnaire have undergone ex-
tensive usability testing, the pilot phase of the RCT
was considered vital in order to assess the interven-
tion over a longer time frame and with all participat-
ing cancer groups as each differ in terms of the care
pathways and staff involved. The decision to perform
an internal pilot, rather than a separate pilot study,
was motivated by our intention to avoid losing mo-
mentum and reduce the time between the end of the
pilot and the start of the main trial [45]. This ap-
proach aimed to maintain continuity with the staff in-
volved in the eRAPID intervention both in terms of
recruitment and utilising the patient AE reports in
clinical encounters.
The study is funded as part of 5 year programme, in
parallel we are developing multi-centre eRAPID inter-
ventions for cancer patients receiving radiotherapy and
surgery which will be evaluated in separate pilot studies.
If found to have a positive effect on patient wellbeing
and use of health care resources, eRAPID has the poten-
tial to provide a cost effective enhancement to the stand-
ard care of cancer patients. Such an approach could also
be extended to long-term survivorship beyond cancer
treatment [49].
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